Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A031801||Alliance||A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RADICAL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A151216||Alliance||Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A221602||Alliance||Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial||Cancer Prevention and Control CIRB||Available to Open|
|A011502||Alliance||A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031704||Alliance||PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]||Adult CIRB - Late Phase Emphasis||Available to Open|
|A221701||Alliance||Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)||Cancer Prevention and Control CIRB||Available to Open|
|A091202||Alliance||A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist; Efatutazone in Patients with Previously Treated; Unresectable Myxoid Liposarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|A031701||Alliance||A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations||Adult CIRB - Late Phase Emphasis||Available to Open|
|A221702||Alliance||ARM: Axillary Reverse Mapping – A Prospective Trial To Study Rates Of Lymphedema And Regional Reccurence After Sentinel Lymph Node Biopsy And Sentinel Lymph Node Biopsy Followed By Axillary Lymph Node Dissection With And Without Axillary Reverse Mapping||Cancer Prevention and Control CIRB||Available to Open|
|A051301||Alliance||A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype||Adult CIRB - Late Phase Emphasis||Available to Open|